📊Trump’s Pharma Tariff Plans Impact Indian Drugmakers

On April 14, 2025, President Donald Trump announced intentions to impose 25% or higher tariffs on imported pharmaceuticals, aiming to bolster domestic manufacturing. ​📉📈 Impact on Indian Pharma- Indian pharmaceutical companies, heavily reliant on the U.S. market, are facing potential challenges:​ Sun Pharma: 32% of revenue from the U.S.​ Dr. Reddy's: 47% of revenue from the U.S.​ Cipla: 30% of revenue from the U.S.​ Biocon: 44% of revenue from the U.S.​ Lupin: 37% of revenue from the U.S.​ Zydus: 46% of revenue from the U.S.​ These companies could see increased costs and reduced competitiveness in the U.S. market. Investor Takeaway: The proposed tariffs introduce significant uncertainty for Indian pharmaceutical companies with substantial U.S. exposure. Investors should monitor developments closely and assess potential risks to their portfolios.🔍📉📈